Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI in locally advanced pancreatic cancer
NCT02351219Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Dec 2012
- Primary completion
- Dec 2014
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and irinotecan in pancreatic cancer (PC), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Rate of patients who become resectable and undergo radical surgical resection at 6 months. Started Dec 2012; status: completed.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02351219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351219.